Tempus AI stock: recent performance and business snapshot

Tempus AI (TEM) has drawn investor attention after a period of weak share performance, with the stock down 3.4% over the past day, 9.3% over the past week, and 21.4% over the past month.

Over the past 3 months the stock has fallen 16.4%, contributing to a year to date decline of 29.6% and a 1 year total return decline of 31.1%, against a market value of about US$7.9b.

The company operates a healthcare technology platform focused on diagnostics, multimodal data, and AI driven tools for clinicians and life sciences customers. It generates revenue of US$1.36b from medical labs and research activities in the United States.

Tempus AI reports annual revenue growth of 16.4% and annual net income growth of 47.5%, while still recording a net loss of US$302.91m. This keeps profitability and cash needs central to many investor conversations around the stock.

For investors, the picture is one of fading momentum, with the share price at US$43.93 after recent declines in short term share price returns and a weaker 1 year total shareholder return.

If Tempus AI’s recent pullback has you reassessing healthcare exposure, it can be useful to see how other AI focused healthcare stocks compare on fundamentals and growth profiles through the 28 healthcare AI stocks

With Tempus AI trading at a discount to some valuation estimates despite solid reported revenue growth and a sizeable net loss, you need to ask: is this a mispriced AI healthcare platform, or is the market already factoring in future growth?

Most Popular Narrative: 34.6% Undervalued

Tempus AI's most followed narrative puts fair value at $67.20, well above the last close at $43.93, which sets up a clear valuation gap for investors to test.

Strong growth in testing volumes and biopharma partnerships positions Tempus AI for durable revenue gains, supported by differentiated technology and a growing data advantage.

Expanding clinical-genomic offerings and disciplined cost management drive improving profitability, while rising AI adoption and regulatory clarity provide long-term growth opportunities.

Want to see what is driving that gap between price and fair value? The narrative leans heavily on accelerating revenue, richer margins and a premium earnings multiple. Curious how those pieces fit together into the $67.20 figure?

Result: Fair Value of $67.20 (UNDERVALUED)

However, this hinges on execution, and setbacks in reimbursement for new assays or pressure on pharma data budgets could quickly challenge that undervalued narrative.

Another angle on Tempus AI’s valuation

While the analyst narrative leans on future earnings and a fair value of $67.20, the current P/S ratio of 5.8x tells a more mixed story. It is higher than both peers at 2.9x and the US Life Sciences average at 3.5x, yet below the fair ratio of 6.6x that the market could shift toward. Is that a margin of safety, or a warning that expectations are already rich?

Next Steps

Uncertain whether the mixed signals in Tempus AI's story lean more positive or negative? Take a closer look at the data now and weigh both sides of the argument with the 2 key rewards and 2 important warning signs.

Looking for more investment ideas?

If Tempus AI has sparked your interest, do not stop here. Broaden your watchlist with other stocks that fit clear, data backed criteria and keep your capital working.

• Target potential value opportunities by reviewing companies flagged in the 51 high quality undervalued stocks.
• Prioritize resilience and sleep a little easier at night by focusing on the 66 resilient stocks with low risk scores.
• Hunt for less crowded opportunities before they hit the spotlight with the screener containing 21 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.